To celebrate the launch of Pharma Strategy Reports, we are offering a complimentary executive summary on Chimeric Antigen Receptor Technology (CAR-T) cell therapy, written by Sally Church, PhD.
You can obtain your complimentary copy of this report on the Pharma Strategy Reports website. You will gain insights into:
- The challenges associated with immunotherapy and stimulating the immune system
- How are next generation immunotherapies making waves in cancer research?
- How recent papers in NEJM and Science & Translational Medicine have described this novel approach and what the preliminary data shows
- Some of the potential challenges or hurdles for registration of CTL019, the CART therapy being developed by Novartis.
CART is emerging as potential new exciting leukemia treatment – impressive results have been reported in a small cohort of adults with CLL and children with ALL who received the Novartis CTL019 therapy.
We expect there will be more data available at the 2013 annual meeting of the American Society of Hematology (ASH) later this year in New Orleans.
If you have an interest in understanding the potential of CART technology, then please sign up at Pharma Strategy Reports to download a complimentary executive summary. You will also be the first to know about future reports when they are published, such as what the new FDA Breakthrough designation means?